OBJECTIVES: To identify demand for Vi typhoid fever vaccine for school-age children; obstacles and enabling factors for vaccine delivery; and socio-behavioural factors associated with trial participation and possible predictors of future vaccine acceptance, in Hue City, Viet Nam. METHODS: Pre- and post-trial surveys of randomly selected households with children aged 6-17 years. Simple multinomial logistic analyses for ratios of relative risks (RRR) and significance on trial participation by demographics and variables related to typhoid fever, vaccination, and pre-trial experiences with information and consents. Multiple logistic regressions to assess differences in participation based on child's characteristics. RESULTS: As many as 62.6% of households let all school age children participate, 10.2% let some participate, and 26.8% let none of their children participate in the trial. Factors associated with all children participating included past use of healthcare facilities (RRR, 0.45; 95% CI, 0.24-0.83), knowledge of vaccines (RRR, 0.17; 95% CI, 0.03-0.86), and perceived causes of typhoid fever (RRR, 0.90; 95% CI, 0.81-0.99). Factors associated with some children participating included utilization of healthcare facilities (RRR, 0.08; 95% CI, 0.01-0.66) and perceived severity of typhoid fever (RRR, 0.64; 95% CI 0.46-0.88). Participation was associated with satisfaction regarding pre-vaccination information and consent procedures. Children and adolescents were active decision-makers. Only 14 of 461 (2.2%) respondents would not use the Vi vaccine in the future for their child(ren). CONCLUSIONS: Inter-related factors contribute to participation in a clinical vaccine trial, which may differ from desire to participate in a public health campaign. Educational campaigns need to be targeted to children and adolescents, and consideration for assent procedures for minors. Obtaining informed consent may affect trial participation within a social and political system unaccustomed to these procedures.
OBJECTIVES: To identify demand for Vi typhoid fever vaccine for school-age children; obstacles and enabling factors for vaccine delivery; and socio-behavioural factors associated with trial participation and possible predictors of future vaccine acceptance, in Hue City, Viet Nam. METHODS: Pre- and post-trial surveys of randomly selected households with children aged 6-17 years. Simple multinomial logistic analyses for ratios of relative risks (RRR) and significance on trial participation by demographics and variables related to typhoid fever, vaccination, and pre-trial experiences with information and consents. Multiple logistic regressions to assess differences in participation based on child's characteristics. RESULTS: As many as 62.6% of households let all school age children participate, 10.2% let some participate, and 26.8% let none of their children participate in the trial. Factors associated with all children participating included past use of healthcare facilities (RRR, 0.45; 95% CI, 0.24-0.83), knowledge of vaccines (RRR, 0.17; 95% CI, 0.03-0.86), and perceived causes of typhoid fever (RRR, 0.90; 95% CI, 0.81-0.99). Factors associated with some children participating included utilization of healthcare facilities (RRR, 0.08; 95% CI, 0.01-0.66) and perceived severity of typhoid fever (RRR, 0.64; 95% CI 0.46-0.88). Participation was associated with satisfaction regarding pre-vaccination information and consent procedures. Children and adolescents were active decision-makers. Only 14 of 461 (2.2%) respondents would not use the Vi vaccine in the future for their child(ren). CONCLUSIONS: Inter-related factors contribute to participation in a clinical vaccine trial, which may differ from desire to participate in a public health campaign. Educational campaigns need to be targeted to children and adolescents, and consideration for assent procedures for minors. Obtaining informed consent may affect trial participation within a social and political system unaccustomed to these procedures.
Authors: Christian Schaetti; Said M Ali; Raymond Hutubessy; Ahmed M Khatib; Claire-Lise Chaignat; Mitchell G Weiss Journal: Hum Vaccin Immunother Date: 2012-08-16 Impact factor: 3.452
Authors: Shantanu K Kar; Alfred Pach; Binod Sah; Anna S Kerketta; Bikash Patnaik; VijayaLaxmi Mogasale; Yang Hee Kim; Shyam Bandhu Rath; Sunheang Shin; Hemant K Khuntia; Anuj Bhattachan; Mahesh K Puri; Thomas F Wierzba; Linda M Kaljee Journal: Hum Vaccin Immunother Date: 2014 Impact factor: 3.452
Authors: Maria Flavia Gazzinelli; Lucas Lobato; Leonardo Matoso; Renato Avila; Rita de Cassia Marques; Ami Shah Brown; Rodrigo Correa-Oliveira; Jeffrey M Bethony; David J Diemert Journal: PLoS Negl Trop Dis Date: 2010-07-20
Authors: Linda M Kaljee; Alfred Pach; Kamala Thriemer; Benedikt Ley; Said M Ali; Mohamed Jiddawi; Mahesh Puri; Lorenz von Seidlein; Jacqueline Deen; Leon Ochiai; Thomas Wierzba; John Clemens Journal: Am J Trop Med Hyg Date: 2012-12-03 Impact factor: 2.345
Authors: Lauren S Blum; Holly Dentz; Felix Chingoli; Benson Chilima; Thomas Warne; Carla Lee; Terri Hyde; Jacqueline Gindler; James Sejvar; Eric D Mintz Journal: Am J Trop Med Hyg Date: 2014-07-07 Impact factor: 2.345
Authors: Joyce L Browne; Connie O Rees; Johannes J M van Delden; Irene Agyepong; Diederick E Grobbee; Ama Edwin; Kerstin Klipstein-Grobusch; Rieke van der Graaf Journal: Trop Med Int Health Date: 2019-01-08 Impact factor: 2.622
Authors: Christian Schaetti; Raymond Hutubessy; Said M Ali; Al Pach; Mitchell G Weiss; Claire-Lise Chaignat; Ahmed M Khatib Journal: BMC Public Health Date: 2009-04-07 Impact factor: 3.295